#China #Shanghai #Biopharmaceutical #CDMO #AsymBio

AsymBio Commences Commercial Operations at Fengxian Base

AsymBio, a subsidiary of the Asymchem Group and a prominent player in the biopharmaceutical Contract Development and Manufacturing Organization (CDMO) sector, has officially begun commercial operations at its Fengxian facility in Shanghai. This significant step marks a notable expansion of the company's capabilities, aimed at bolstering the development and production of innovative therapies for global markets.

Strategic Importance of the Fengxian Base

Spanning over 130,000 square meters, the Fengxian base is designed to serve as a critical hub within AsymBio's worldwide network. It complements the existing Shanghai Jinshan Base and Zhangjiang Center for Biological Technology and Innovation, allowing the company to offer a comprehensive suite of biologics CDMO services. This facility is meticulously engineered to provide adaptable and scalable support across various clinical phases, empowering clients with tailored solutions that range from early development stages to commercial manufacturing.

Advanced Manufacturing Capabilities

At the heart of the Fengxian operation are its advanced manufacturing capabilities. The facility is prepared to produce a diverse range of therapeutic biologics, including Antibody Drug Conjugates (ADCs), dual-payload ADCs, Recombinant Proteins, and various forms of monoclonal and bispecific antibodies. The infrastructure includes:

• - Phase IA dedicated to antibody manufacturing, featuring single-use bioreactors with capacities of 200L, 500L, and 2000L, aggregating a total production capacity of 66,000 liters of drug substance annually. Additionally, it is equipped with a lyophilizer capable of producing up to one million vials of lyophilized antibody drug product each year.
• - Phase IB focuses on bioconjugate manufacturing and is furnished with 200L and 500L reactors to cater to all clinical phases. The facility supports both clinical-scale and commercial-scale drug product lines, with the ability to yield up to two million vials annually through its robust lyophilization capabilities.

Leadership Insights

Rui Yang, the CEO of AsymBio, emphasized the strategic significance of the Fengxian base amid the company’s growth trajectory. "The launch of our Fengxian Base represents a pivotal point in AsymBio's global expansion strategy. By effectively merging our Jinshan and Fengxian facilities, we are significantly enhancing our production capabilities and enabling streamlined service delivery for our clients around the world. This development not only strengthens our production pipeline but also reinforces our commitment to fostering biopharmaceutical innovation."

Commitment to Quality and Sustainability

Commitment to high-quality standards and sustainable practices is at the forefront of Fengxian's operations. The manufacturing facility adheres to a stringent quality management system that aligns with the regulations of leading global authorities. AsymBio employs state-of-the-art biomanufacturing technologies that promise cost efficiencies and provide flexible solutions, standing in contrast to traditional stainless-steel manufacturing methods. The site exemplifies Asymchem’s dedication to Environmental, Social, and Governance (ESG) strategies as well as robust EHS management principles.

About AsymBio

As a strategic entity of Asymchem Group, AsymBio focuses on biopharmaceutical CDMO services, leveraging cutting-edge technology and extensive project experience to deliver comprehensive solutions for its global clientele. From early-stage research and process development to toxicology and clinical batch manufacturing, AsymBio is committed to advancing the field of novel biotherapeutics.

For further insight into their operations and offerings, visit AsymBio's website or connect with them on LinkedIn.

Business Inquiries: For additional information, contact [email protected]

Disclaimer: This release includes forward-looking statements about future events and expectations that are subject to risks and uncertainties. Actual results may differ significantly. AsymBio does not promise to update these statements. This message serves informational purposes only and does not constitute an investment offer.